Literature DB >> 2156728

Characterization of high-affinity receptors for truncated glucagon-like peptide-1 in rat gastric glands.

L O Uttenthal1, E Blázquez.   

Abstract

The truncated form of glucagon-like peptide-1 (TGLP-1, or proglucagon 78-108), secreted by the mammalian intestine, has potent pharmacological activities, stimulating insulin release and inhibiting gastric acid secretion. We have characterized high-affinity receptors for this peptide in rat isolated fundic glands. Scatchard analysis of binding studies using mono-125I-TGLP-1(7-36) amide as tracer showed a single class of binding site of Kd (4.4 +/- (SE) .08) x 10(-10) M, with a tissue concentration of 1.0 +/- 0.1 fmol sites/microgram DNA. Whole GLP-1 was approximately 700 times less potent in displacing tracer, while human GLP-2 and pancreatic glucagon produced no significant displacement at concentrations up to 10(-6) M. The data support a physiological role for TGLP-1 in the regulation of gastric acid secretion.

Entities:  

Mesh：

Substances：

Year:  1990        PMID： 2156728     DOI： 10.1016/0014-5793(90)80173-g

Source DB:  PubMed          Journal:  FEBS Lett        ISSN： 0014-5793            Impact factor:   4.124


  13 in total

1.  Truncated and full-length glucagon-like peptide-1 (GLP-1) differentially stimulate intestinal somatostatin release.

Authors:  P L Brubaker; S Efendic; G R Greenberg
Journal:  Endocrine       Date:  1997-02       Impact factor: 3.633

Review 2.  Imaging beta-cell mass and function in situ and in vivo.

Authors:  Lu Yang; Wei Ji; Yanhong Xue; Liangyi Chen
Journal:  J Mol Med (Berl)       Date:  2013-05-23       Impact factor: 4.599

3.  Glucagon-like peptide-1: a potent regulator of food intake in humans.

Authors:  J P Gutzwiller; B Göke; J Drewe; P Hildebrand; S Ketterer; D Handschin; R Winterhalder; D Conen; C Beglinger
Journal:  Gut       Date:  1999-01       Impact factor: 23.059

4.  GLP-1 receptor is expressed in human stomach mucosa: analysis of its cellular association and distribution within gastric glands.

Authors:  Efrat Broide; Olga Bloch; Gilad Ben-Yehudah; Dror Cantrell; Haim Shirin; Micha J Rapoport
Journal:  J Histochem Cytochem       Date:  2013-06-26       Impact factor: 2.479

Review 5.  The effect of glucagon-like peptide 1 on cardiovascular risk.

Authors:  Jacob Sivertsen; Jaya Rosenmeier; Jens J Holst; Tina Vilsbøll
Journal:  Nat Rev Cardiol       Date:  2012-01-31       Impact factor: 32.419

6.  Diabetes and insulin-induced stimulation of L-arginine transport and nitric oxide synthesis in rabbit isolated gastric glands.

Authors:  R Contreras; O Fuentes; G E Mann; L Sobrevia
Journal:  J Physiol       Date:  1997-02-01       Impact factor: 5.182

7.  Glucagon-like peptide-1 stimulates luteinizing hormone-releasing hormone secretion in a rodent hypothalamic neuronal cell line.

Authors:  S A Beak; M M Heath; C J Small; D G Morgan; M A Ghatei; A D Taylor; J C Buckingham; S R Bloom; D M Smith
Journal:  J Clin Invest       Date:  1998-03-15       Impact factor: 14.808

8.  Protein kinase C inhibits cyclic adenosine monophosphate generation by histamine and truncated glucagon like peptide 1 in the human gastric cancer cell line HGT-1.

Authors:  P McKenna; J M Williams; C P Gespach; P J Hanson
Journal:  Gut       Date:  1993-07       Impact factor: 23.059

Review 9.  Glucagon-like peptide-1, a new hormone of the entero-insular axis.

Authors:  C Orskov
Journal:  Diabetologia       Date:  1992-08       Impact factor: 10.122

Review 10.  Emerging cardiovascular actions of the incretin hormone glucagon-like peptide-1: potential therapeutic benefits beyond glycaemic control?

Authors:  David J Grieve; Roslyn S Cassidy; Brian D Green
Journal:  Br J Pharmacol       Date:  2009-08       Impact factor: 8.739
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.